The Circular Economy Act (CEA) aims to advance the EUs transition to a circular economy by fostering a single market for circular products, secondary raw materials, and waste. It supports the goals of the Clean Industrial Deal, Competitiveness Compass, and Draghi report by strengthening economic resilience, decarbonisation, and reducing dependency on non-EU raw materials.
VFA
Verband Forschender Arzneimittelhersteller (vfa)
Industry association · Germany · EU Transparency Register 9796640403-95
3
positions filed
in the 665 files tracked
3
legislative files
of 665 tracked
2
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1518 trade and business associations on this site, they rank #946 by legislative files engaged, a count of participation, not a measure of influence.
2.9
declared lobbying FTE
self-declared
€200K+
declared costs / yr (floor)
0
EP accreditations
as declared to the register
2008
in the register since
Declares membership of
- Der vfa ist Mitglied im Weltverband (IFPMA) und im Europäischen Verband (EFPIA) der forschenden Arzneimittelhersteller.
- www.efpia.eu
- www.ifpma.org
- Darüber hinaus pflegt der vfa enge Kontakte zu anderen nationalen Pharmaverbänden. Das erweiterte Netzwerk des vfa um…
- Der vfa ist im nationalen Transparenzregister registriert.
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026).
- Register category
- Trade and business associations
- Registered as
- Verband Forschender Arzneimittelhersteller e.V. (vfa)
- Head office
- Berlin, Germany
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Verband in PolicySpeak: request access →
Work at Verband Forschender Arzneimittelhersteller (vfa)? so we know who speaks for it.
Their record over time
Verband Forschender Arzneimittelhersteller (vfa) filed 3 positions between 5 Jan 2021 and 3 Nov 2025, across 3 of the 665 legislative files tracked here, attaching a full position paper 2 times.
2021 · 2 filed2025 · 1 filed
What they argued
A vital innovation ecosystem accompanied by an agile regulatory framework are prerequisites for a modern pharmaceutical system. Therefore, the German Association of Research-Based Pharmaceutical Companies (vfa), representing 47 of the world’s leading research-based pharmaceutical companies, welcomes the initiative by the Eu-ropean Commission to review the long-standing general pharmaceuti-cal legislation.
The German Association of research-based pharmaceutical companies (vfa) welcomes that the European Commission (EC) is focusing on unmet medical needs (UMN). The current range of therapies for the treatment of patients with rare diseases (RD) and of children is encouraging and has been boosted by different EU initiatives over the past.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Verband Forschender Arzneimittelhersteller (vfa) next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 66.
Is this your organization?
Everything on this page comes from Verband Forschender Arzneimittelhersteller (vfa)’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.